C-reactive protein and implications in rheumatoid arthritis and associated comorbidities.
Journal
Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
16
06
2020
revised:
19
10
2020
accepted:
05
11
2020
pubmed:
2
1
2021
medline:
30
9
2021
entrez:
1
1
2021
Statut:
ppublish
Résumé
C-reactive protein (CRP) is routinely assessed as a marker of systemic inflammation in rheumatoid arthritis (RA). However, it is also an immune regulator that plays an important role in inflammatory pathways associated with RA and promotes atherogenic effects. Comorbidities linked to systemic inflammation are common in RA, and CRP has been associated with the risk for cardiovascular disease, diabetes, metabolic syndrome, pulmonary diseases, and depression. The relationship between systemic inflammation, CRP, and comorbidities in RA is complex, and it is challenging to determine how changing CRP levels may affect the risk or progression of these comorbidities. We review the biological role of CRP in RA and its implications for disease activity and treatment response. We also discuss the impact of treatment on CRP levels and whether reducing systemic inflammation and inhibiting CRP-mediated inflammatory pathways may have an impact on conditions commonly comorbid with RA.
Identifiants
pubmed: 33385862
pii: S0049-0172(20)30290-0
doi: 10.1016/j.semarthrit.2020.11.005
pii:
doi:
Substances chimiques
Biomarkers
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
219-229Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.